Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +50

Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates

📈 Amgen reported Q1 earnings of $5.15 per share, exceeding the consensus estimate of $4.73 and beating last year's figures of $4.90.

🏆 The company achieved an 8.87% positive earnings surprise compared to the quarterly expectation of $4.76 per share.

📊 Amgen generated Q1 revenues of $8.62 billion, surpassing analyst estimates by 1.71% against a year-ago total of $8.15 billion.

✅ The company has outperformed consensus EPS estimates in all four consecutive quarters reported so far.

📉 Since the start of the year, Amgen shares have gained approximately 3.3%, trailing the S&P 500's 4.2% return.

⚠️ Based on mixed estimate revision trends prior to the report, the stock currently holds a Zacks Rank #3 (Hold).

🔮 Analysts maintain a forward consensus EPS estimate of $5.79 per share for the upcoming quarter with revenues projected at $9.45 billion.

🌍 The broader Medical - Biomedical and Genetics industry rank is in the bottom 41%, suggesting potential underperformance relative to top-ranked sectors.

⏳ Tarsus Pharmaceuticals (TARS), a peer company in the same sector, is yet to release its Q1 results but expects a loss of $0.43 per share.

📈 Tarsus is anticipated to report revenues of $149.52 million, representing a 90.9% increase from the previous year's quarter.

🔄 Recent research indicates a strong correlation between earnings estimate revision trends and near-term stock price movements.

📄 Amgen belongs to the Zacks Medical - Biomedical and Genetics industry which currently faces mixed outlook conditions.

Bullish Signals
  • Amgen reported quarterly earnings of $5.15 per share, surpassing the Zacks Consensus Estimate of $4.73 per share by 8.87%.
  • Revenues reached $8.62 billion for the quarter ended March 2026, exceeding analyst estimates and showing year-over-year growth from $8.15 billion.
  • The company has topped consensus revenue estimates four times over the last four consecutive quarters.
  • Over the past four quarters, Amgen has surpassed consensus EPS estimates on four out of four occasions, demonstrating consistent operational strength.
  • Earnings per share increased to $5.15 compared to $4.90 a year ago, reflecting adjusted growth even when accounting for non-recurring items.
Risk Factors
  • Amgen shares have underperformed the S&P 500 so far this year, gaining only 3.3% compared to the index's 4.2% return.
  • The Zacks Rank for Amgen is currently a #3 (Hold), indicating the stock is expected to perform in line with the market rather than outperforming.
  • The 'Medical - Biomedical and Genetics' industry ranks in the bottom 41% of all Zacks industries, creating a structural headwind for the company.
  • Industry research suggests that top 50% industries outperform the bottom 50% by more than 2 to 1, putting Amgen at a relative disadvantage.
  • Although the quarterly and fiscal year estimates are positive, management commentary on sustainability will be a key variable that could lead to further downside if expectations are not met.
Full Analysis
Amgen Inc. (AMGN) reported its Q1 earnings for the quarter ended March 2026, posting quarterly earnings per share of $5.15, which exceeds the Zacks Consensus Estimate of $4.73. On an adjusted basis excluding non-recurring items, the company's earnings were $5.15, representing a significant year-over-year increase from $4.90 in the same quarter last year. This performance resulted in an earnings surprise of +8.87% against the consensus, following a previous quarter where the company beat estimates by 11.13%, having surpassed expectations four times over the trailing four quarters. Revenue for the quarter reached $8.62 billion, surpassing the consensus estimate by 1.71%, and also marking an increase from year-ago revenues of $8.15 billion. Consequently, Amgen has topped consensus revenue estimates for four consecutive quarters. Despite beating quarterly earnings and revenue expectations, Amgen shares have underperformed the broader market in 2026, gaining approximately 3.3% compared to the S&P 500's gain of 4.2%. The future sustainability of the stock's price movement is expected to rely heavily on management's commentary during the earnings call and trends in earnings estimate revisions for upcoming periods. Currently, Amgen carries a Zacks Rank #3 (Hold), as mixed estimate revisions prior to the report suggest shares may perform in line with the market until further changes occur. Analysts note that investors should monitor how consensus expectations for the coming quarter ($5.79 EPS on $9.45 billion revenue) and the current fiscal year ($22.17 EPS on $37.78 billion revenue) evolve, as these revisions often correlate strongly with near-term stock performance. The article also highlights industry dynamics within the Zacks Medical - Biomedical and Genetics sector, which is currently ranked in the bottom 41% of over 250 industries tracked by Zacks Investment Research. Historical data indicates that stocks in the top 50% of industries tend to outperform those in the bottom 50% by a factor of more than two-to-one. While Amgen has strong recent fundamentals, its industry peer Tarsus Pharmaceuticals Inc. (TARS) is expected to report quarterly results showing a loss of $0.43 per share for the quarter ended March 2026, with revised revenue estimates at $149.52 million. The overall outlook for Amgen and the broader biotech sector may be influenced by these industry-wide trends and how other companies in the same space perform as they report their own figures.